Navigation Links
WuXi PharmaTech Announces Third Quarter 2008 Results
Date:11/12/2008

Third Quarter Net Revenues Up 98% and Adjusted EBITDA Up 70% Year-Over-Year

SHANGHAI, China, Nov. 12 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced its unaudited financial results for the third quarter ended September 30, 2008. During the quarter, WuXi's net revenue increased 98% year-over-year to $67.5 million, and diluted earnings per ADS were $0.10.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Commenting on the third quarter 2008 results, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, said, "WuXi continues to deliver strong revenue and profitability growth, as reflected in 98% year-over-year top-line revenue and 70% adjusted EBITDA growth. As we disclosed in the pre- announcement, the constricted biotech financing environment is impacting the CRO industry. However, we believe the need for outsourced development and manufacturing services will continue to be robust in the longer term. WuXi will continually work with WuXi's customers to bring their programs from bench to the market sooner and less costly.

"We are dedicated to maintaining and expanding WuXi's preferred provider status with our customers. In addition to delivering high-quality, IP- protected services efficiently, we will continue to position WuXi for the future to improve the success of discovery and shorten development time for our customers. This commitment requires us to expand WuXi's capacity and capabilities to meet our customers' expanding
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
2. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
3. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
4. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
5. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
6. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
7. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
8. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
9. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
10. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
11. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Selexis SA, a serial ... Cell Banks (RCBs) used for drug discovery to commercial ... will include Next-Generation Sequencing (NGS) data packages. ... biologic manufacturing by ensuring the integrity of the gene, ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
(Date:12/24/2014)... and NEW YORK , Dec. ... biopharmaceutical company advancing patient care in critical areas, announced the ... common stock, and warrants to purchase up to an aggregate ... $4.00 per share and $.01 per warrant.  The warrants have ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... /Xinhua-PRNewswire-FirstCall/ -- China,Pharma Holdings, Inc. ("China Pharma") ... markets generic and branded bio/pharmaceutical,products in China, ... LLP (SIG)"Beijing Management Summit" held in Beijing, ... September 2008., Attending this conference and ...
... September 1 , With some 20,000 UK ... the,new school year, new guidance from the National ... to revolutionise the way children,manage their diabetes, granting ... access to insulin pump therapy. The new,recommendations finally ...
... the electrical units of voltage, resistance and current ... nowadays used. Important prerequisites are extremely pure semiconductor ... without collision with residual impurities. To be prepared ... set up a new molecular beam epitaxy system ...
Cached Biology Technology:British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines 2British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines 3British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines 4'Racetrack' for fast electrons in semiconductor structures 2
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ...
(Date:12/10/2014)... 2014 You,ve been here before: you desperately need to sign ... key or the answer to your secret question. What,s your dog,s ... Hoyos Labs , a digital infrastructure security company, launches ... frustration that comes with usernames, passwords and PINs – 1U ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a new ... this $50 million capital project is part of a larger ... The medical education building will be located in ... to 525@vine in Wake Forest Innovation Quarter. Construction will begin ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Assistant Professor Frank J. Slack at Yale University has identified ... lung cancer, presenting new possibilities for diagnosis and treatment. The ... and Developmental Cell. , The oncogene Ras is out of ... over-expressed or activated by mutation. According to Slack, a member ...
... to block cat allergies successfully prevented allergic reactions in ... a test tube, University of California, Los Angeles (UCLA) ... available online now. In the future, the investigators say, ... not only for human cat allergies, but also possibly ...
... Researchers have created a way to transform the dead bone ... experiment involving mice. The advance, which uses gene therapy to ... bone, is a promising development for the thousands of cancer ... failing bone grafts. The findings were posted online Feb. 13 ...
Cached Biology News:Yale Scientists Find MicroRNA Regulates Ras Cancer Gene 2Novel Therapy Tested in Mice Could Chase Away Cat Allergies 2Novel Therapy Tested in Mice Could Chase Away Cat Allergies 3Gene therapy converts dead bone graft to new, living tissue 2Gene therapy converts dead bone graft to new, living tissue 3Gene therapy converts dead bone graft to new, living tissue 4
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
... Binding: High, 400 ng IgG/cm 2 ... Interaction: Hydrophobic/Ionic , Performance Certified: Well-to-Well, CV ... Maximum Well Volume: 360 µl , Packaging: ... ,Features, Special optically clear polystyrene formulation , ...
...
... Grace's medium was originally formulated to ... the Australian emperor gum moth,Antherea eucalypti. The ... to more closely resembleAnthereahemolymph. The cell lines ... the first continuous lines developed. The basal ...
Biology Products: